EN
菜单
Leadership
Board of Directors
Management Team
Henlius has assembled a team of highly-skilled talents with extensive experience across research & development, clinical development, manufacturing, commercialisation, regulatory affairs, CMC, quality and compliance, etc. at leading multinational pharmaceutical companies.
Dr. Jun Zhu (朱俊) is currently an executive Director and the chief executive officer of the Company. Dr. Zhu joined the Group in January 2021 and served as the senior vice president and chief medical officer of Henlius Biopharmaceutical, and the senior vice president and chief medical officer, chief financial officer and president of the Company.

" />
Dr. Jun Zhu
Executive Director
Dr. Xingli Wang is currently a non-executive Director and the Chairman of the Board. Dr. Wang joined Fosun Pharma Group in January 2023, served as an executive president and the co-president of Fosun Pharma and currently serves as the President of Fosun Pharma.


" />
Dr. Xingli Wang
Chairman & Non-executive Director
Mr. Qiyu Chen (陳啟宇) is currently a non-executive Director of the Company. Mr. Chen served as the Chairman of the Board of the Company from December 2018 to November 2021. Mr. Chen currently serves as the non-executive director of Fosun Pharma, the chairman of the board of Fosun High Tech, the executive director and the co-chief executive officer of Fosun International, the non-executive director and vice chairman of the board of Sinopharm. 

" />
Mr. Qiyu Chen
Non-executive Director
Mr. Yuqing Chen (陳玉卿) is currently a non-executive Director of the Company. Mr. Chen is currently an executive director and the chairman of the board of directors of Fosun Pharma, a senior vice president of Fosun International, and a non-executive director of Sinopharm. 


" />
Mr. Yuqing Chen
Non-executive Director
Ms. Xiaohui Guan (關曉暉) is currently a non-executive Director of the Company. Ms. Guan is currently an executive director and a co-chairman of Fosun Pharma, the vice president of Fosun International and the chairman of the board of supervisors of Sinopharm. 

" />
Ms. Xiaohui Guan
Non-executive Director
Dr. Yi Liu (劉毅) is currently a non-executive Director of the Company. Dr. Liu currently serves as an executive director, chief executive officer of Fosun Pharma and a non-executive director of Sisram Medical. 


" />
Dr. Yi Liu
Non-executive Director
Mr. Tak Young So (蘇德揚) is currently an independent non-executive Director of the Company. Mr. So has more than 30 years of experience in finance, accounting, investment, and private equity businesses with global financial institutions and asset management companies. Mr. So currently serves as the founding and managing partner of FastLane Group.

" />
Mr. Tak Young So
Independent Non-executive Director
Dr. Lik Yuen Chan (陳力元) is currently an independent non-executive Director of the Company. Dr. Chan is a world-famous academic in liver diseases with extensive achievements and recognition in clinical practice and research teaching. Dr. Chan currently serves as the vice president and manager of the Internal Medicine Department of Hong Kong Union Hospital.


" />
Dr. Lik Yuen Chan
Independent Non-executive Director
Dr. Ruilin Song (宋瑞霖) is currently an independent non-executive Director of the Company. Dr. Song currently serves as the senior president of PhIRDA (中國醫藥創新促進會), the non-executive director of Luye Pharma Group Ltd.* (綠葉製藥集團有限公司) (Stock Exchange stock code: 02186), the independent non-executive director of Simcere Pharmaceutical Group Limited* (先聲藥業集團有限公司) (Stock Exchange stock code: 02096), the independent non-executive director of Jacobio Pharmaceuticals Group Co., Ltd.* (加科思藥業集團有限公司) (Stock Exchange stock code: 01167), and the independent non-executive director of Mediwelcome Healthcare Management & Technology Inc.* (麥迪衛康健康醫療管理科技股份有限公司) (Stock Exchange stock code: 02159).


" />
Dr. Ruilin Song
Independent Non-executive Director
Dr. Jason Zhu is the Executive Director and Chief Executive Officer. Jason has more than 20 years in clinical research industry. He had cooperated with over 70 China local pharmaceutical and biotech companies and led the design and execution of over 100 phase I to IV clinical trials. Prior to joining Henlius, Jason was Founder and CEO of PPC China, Global Vice President of IQVIA, China GM of Omnicare. Jason had previously worked as a physician in Huashan Hospital for two years. 
" />
Jason Zhu
Executive Director & Chief Executive Officer
Ms. Wei Huang, President, is in charge of the Global Manufacturing Engineering Technology Department, responsible for the production and supply of the Company's clinical and commercial products, the design and implementation of engineering projects, and the continuous improvement and optimization of production capacit. Ms. Huang holds Bachelor degree from East China University of Science and Technology in Biochemical Engineering, Master degree from University of Maryland in Chemical and Biochemical Engineering. Prior to joining Henlius, Ms. Huang has Senior management and leadership experience in pharmaceutical and biotechnology industry spanning over 30 years in process development, technology transfer, manufacturing, process and facility design, capital project execution, and quality system implementation.
" />
Wei Huang
President
Mr. Kurt Yu, Senior Vice President and Chief Commercial Officer, is in charge of the Marketing and Commercial Operations Department and the Medical Affairs Department, responsible for the commercial operations. Prior to joining Henlius, Mr. Yu has over 20 years’ experience in sales and central marketing management (for Glaxo Wellcome, Roche and Amgen) with different roles including medical representative, product manager, district sales manager, marketing manager, and marketing director/ head. He has rich experience in portfolio management, marketing strategy development, new product launch etc.

Mr. Yu graduated from Shanghai Medical University with bachelor degree in pharmaceutical chemistry. Then he obtained the EMBA degree from Fudan University.
" />
Kurt Yu
Chief Commercial Officer & SVP
Ms. Ping Cao, Senior Vice President and Chief Business Development Officer, is in charge of the Business Development Department, responsible for the Company's business cooperation with external partners, including licensing in and out, authorization, partnership alliance, merger and acquisition. Ms. Cao graduated from Tianjin University with a BS in Material Science & Engineering and MS in Chemical Engineering and obtained her MS in Organic Chemistry at Michigan State University. She previously worked at Tyger Scientific, Ferro, Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. Director of Business Development. At Tyger Scientific, Ms. Cao increased the business revenue 600% in 4 years. At BMS, she was responsible for global business development at CMO (contract manufacture operation) and accomplished significant sales growth. Then Ms. Cao joined business development team focusing on technology transactions. She evaluated, negotiated and executed 36 technology collaboration deals to expedite the company’s drug discovery and development process. As a reward for her accomplishment, Ms. Cao received the Distinguished Employee Award, Innovation Award etc. at BMS. At Abzena, she developed and executed the business strategy of offering integrated contract manufacture service of biologics and antibody drug conjugates based on company core technologies of antibody drug conjugation and humanization, which greatly enhanced the company’s business growth worldwide.
" />
Ping Cao
Chief Business Development Officer & SVP
Dr. Simon Hsu holds PhD degree from Purdue University in Biochemical Engineering, Master degree from Ohio State University in Biochemical Engineering, and Bachelor degree from National Tsing Hua University in Chemical Engineering. Dr. Simon Hsu has over 2 8 years of management and research experience in the pharmaceutical industry . He has directed and successfully managed more than 25 antibody and recombinant protein projects of technology transfer, scale up and process validation up to 40,000 L Prior to joining Henlius, he served for leading enterprise in pharmaceuticals ind ustry, such as GenSci , HuiGene Therapeutics , Henlius, Pieris, Shire, Bristol Myers Squibb MedImmune AstraZeneca )), Alexion AstraZeneca etc . Dr. Simon Hsu has extensive experience and technology in process development, production, quality control, project management, international registration, licensing applications, clinical to market commercialization, and continuous bioprocess etc.
" />
Simon Hsu
Chief Technology Officer & SVP
In addition, he is the member of the Pharmaceutical Innovation Investment Specialty Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA), the vice-chairman of Shanghai Biopharmaceutics Industry Association (SBIA) and the member of the 9th council of Shanghai Pharmaceutical Profession Association (SPPA). " />
James Guo
SVP
Ms. Jessie Li, Senior Vice President and Chief Human Resource Officer, is responsible for overall HR strategy, organization development, talent strategy. Ms. Jessie Li brings with her over 20 years of HR management experiences, and prior to joining Henlius, she worked in TCCP, Astra Zeneca, De Lage Landen, Kodak Healthgroup/Carestream as HRVP, Executive HR Director, Head of China HR. Ms. Jessie Li holds Bachelor degree from Shandong Finance University in International Finance in 1998, and MBA from Shanghai University of Finance and Economics – Webster University in 2002.
" />
Jessie Li
Chief Human Resource Officer & SVP
Dr. Jiyun Yuan, Chief Scientific Officer (CSO), is responsible for the overall strategic planning, team management and daily operations of Innovation Center. Dr. Yuan has extensive experience and outstanding achievements in leading innovative drug research and development and building innovative early research team. He has achieved remarkable results in preclinical research and development, clinical trial applications, patent applications and intellectual property transfers of antibody drugs. Dr. Yuan’s research and development work covers a wide range of drugs, including antibodies, CAR-T, mRNA, and small molecules etc. Prior to joining Henlius, Dr. Yuan  served as Deputy Director of Biology Department of Shanghai Hengrui Medical Co., Ltd., Vice President & Chief Scientific Officer of Shanghai Genechem Co., Ltd., General Manager of Shanghai Genbase Biotechnology Co., Ltd. (wholly owned subsidiary of Shanghai Genechem Co., Ltd.), and President of Preclinical Development of Suzhou Abogen Biosciences Co., Ltd. Dr. Yuan holds a Ph.D. in Biochemistry from The Ohio State University in the United States and completed his postdoctoral research in Molecular Biology at the University of California. He earned his bachelor's degree in Biochemistry from Fudan University.
" />
Jijun Yuan
Chief Scientific Officer
Mr. Max Mao, Vice President and Chief Financial Officer, is responsible for corporate financial strategy and planning, financial operation management, etc. Max holds his MBA degree of BI Norwegian Business School - Fudan University MBA Program and bachelor’s degree in economics with major in international accounting from Shanghai University of Finance and Economics. Max is a Certified Public Accountant and holds a legal professional qualification in China. Prior to joining Henlius, Mr. Max Mao has more than 20 years of experience in financial related, he joined Fosun Group in March 2019 and successively served as Chief Financial Officer of Health Holdings, Deputy Chief Financial Officer and General Manager of Finance Department of the Great Health Industry Operating Committee, and Co-chief Financial Officer and General Manager of Finance Department of the Health Industry Committee. Before that, he took a role as key financial management positions in companies such as Deloitte, Coca-Cola, Bayer Pharma and UCB.


" />
Max Mao
Chief Financial Officer & VP
Mr. Ming Yang, Vice President of the Immune-Oncology Business Unit, is mainly responsible for the promotion of immune-oncology products of the Company. Before joining Henlius, Ming served as important positions of many large multinational enterprises, such as Bristol-Myers Squibb, AstraZeneca, Roche, and Bayer. He has more than 20 years working experience in tumor immunity filed and led some blockbuster product launches in China such as Opdivo. Mr. Yang has rich experience in sales strategy development, commercial operation, and sales system establishment.

" />
Ming Yang
VP of Immune-Oncology Business Unit
Mr. Jing Li, Vice President of Global Product Development, is responsible for the global strategic planning and operational management of Global Product Development Department. During over 15 years on clinical research, he has successfully launched the first biosimilar drug in China (HANLIKANG), the first EMA approved biologic product from China (HANQUYOU), and managed over 80 clinical trials, covering clinical phase 1 to Phase 4 trials. Before joining Henlius, he worked for Hutchison, Roche, Covance and SPH. He has the master's degree of medicine from Tongji University.
" />
Jing Li
VP of Global Product Development
Ms. Li Jin, Vice President of Regulatory Affairs, is responsible for the global strategic planning and operational management of Regulatory Affairs Department. Ms. Li Jin graduated from Beijing University of Chinese Medicine with a Bachelor’s degree in Traditional Chinese Medicine. She has about 22 years experience in regulatory affairs. Prior to joining Henlius, she held the key position in many different types of companies, including local and multi-national ones, for example Nuance, Mundi Pharma, Merck Serono, Amgen, MSD and China Grand Enterprises, etc. She also had 5 years medicine research experience in pharmaceutical R&D center. Her ability to control different stages of different products is excellent due to previous experienced in various types of companies, including small molecular, biological and medical device products, etc. In addition, she has rich team management skill, especially on team building up and member development. 
" />
Jin Li
VP of Regulatory Affairs
Ms. Miaojie Chen, VP of Legal and Compliance, is responsible for the management and improvement of the legal and compliance system, supporting the planning and implementation of the sustainable development of company's legal and compliance, and supporting company's major projects.

Miaojie holds her Master degree from Illinois Institute of Technology, Chicago-Kent College of Law and Bachelor degree from East China University of Politics and Law. Miaojie was admitted to practice as an attorney at law in both New York State and PRC. And she has rich experiences both in top law firm and inhouse of pharmaceutical.
Prior to joining Henlius, Miaojie was the VP of Legal and general counsel in Eddingpharm Group, responsible for IPO, financing and investment, BD license-in & technology transfer deal, general corporate governance, and compliance.

" />
Miaojie Chen
VP of Legal and Compliance
Ms. Nancy Wang, Vice President and Board Secretary, Secretary to the Board and Joint Company Secretary of the Company, being responsible for the operational management of Office of Secretary to the Board, Information Public Relations Department, Administration Department, Business Public Relations Department, Sales Training Department, Project Management Department and other departments. Previously, Ms. Wang has successively acted as Supervisor of the Marketing Department, Securities Affairs Representative and Manager of Public Affairs Department, Director of the Office of Board Secretary, General Manager of Public Relations of the Company. Ms. Wang obtained her Bachelor’s degree in Bio-pharmacy from Nanjing Forestry University in 2010 and a Master’s degree in Biochemistry in 2013 from the same university.

" />
Nancy Wang
Board Secretary & VP
Dr. Qingyu Wang, Chief Medical Officer, is responsible for establishing global clinical development strategies. With a strong academic background and extensive industry experience, she excels at integrating medical, commercial, and regulatory requirements to develop strategic plans. Dr. Wang holds an MD degree and completed postdoctoral training at Shanghai Jiao Tong University. With 10+ years of end-to-end clinical development leadership, she has spearheaded the global clinical development and approval of multiple blockbuster biologics. Known for her rigorous approach and big-picture perspective, she combines scientific precision with strategic vision.

" />
Qingyu Wang
Chief Medical Officer
Darius Panaligan, Chief Commercial Officer, International Markets, is primarily responsible for executing of Biosimilar global and Innovative Drug European business strategies and building teams guided by Henlius’ overall business priorities and market potential, to advance the company’s global expansion. 


Darius brings over 30 years of experience in pharma industry with expertise in launches, commercialization, organizational transformation, market expansion, global partnering and communications. He has worked in local markets in Europe, the United States, Canada, and Indonesia, covering mature and emerging markets worldwide, with commercialization across oncology, autoimmune, cardiovascular metabolism, and respiratory therapeutic areas.


Prior to joining Henlius, Darius held various leadership positions over a 15-year tenure at Novartis and Sandoz and 10-year tenure at Fresenius Kabi in a wide range of commercial leadership roles at Country, Regional and Global levels. In his most recent role at Fresenius Kabi as Senior Vice President, Head of EU&ROW Biopharma, Darius successfully led country and cluster Teams to achieve significant growth in revenue and profitability with multiple and sequential launches over the last 5 years. He led the expansion of the Biopharma business and teams across multiple regions.   


Darius holds a Bachelor of Science Degree in Biology from the University of British Columbia, also holds Master of Business Administration from the Simon Fraser University, and Executive Education from Tuck University at Dartmouth and from the Harvard Business School.



" />
Darius Panaligan
Chief Commercial Officer, International Markets
Mr. Guangri Sun, General Manager of the Oncology Business Unit, is accountable for the promotion of the company's oncology portfolio. Prior to joining Henlius, Mr. Sun accumulated over 16 years of pharmaceutical industry experience through progressively senior roles at companies including Zai Lab, AstraZeneca, and Eli Lilly. He possesses extensive expertise in team building, execution of key market strategies, and innovative sales model development, having successfully driven growth for multiple oncology products throughout his career.

" />
Guangri Sun
GM of Oncology Business Unit
K. Christopher Garcia, Ph.D is a Professor of Molecular and Cellular Physiology, and of Structural Biology at the Stanford University School of Medicine.  He received his B.S. in Biochemistry from Tulane University, and his Ph.D in Biophysics from Johns Hopkins University. Dr. Garcia was elected to the National Academy of Sciences in 2012, and the National Academy of Medicine in 2016.


Dr. Garcia’s interests reside at the cell surface, and his laboratory is investigating structural and functional aspects of cell surface receptor recognition and activation, in receptor-ligand systems with relevance to human health and disease. A common theme is that structural information on receptor-ligand complexes is used to engineer variant proteins and/or surrogates to manipulate receptor signaling and cellular function, as well as act as biological probes to perturb systems in vivo, with an eye towards therapeutic applications. The receptor systems studied derive principally from the immune system (TCR/MHC, cytokines, chemokine GPCR), but additionally encompass several systems that are also important in neurobiology (Neurotrophins, Semaphorins) and development (Notch, Wnt). Dr. Garcia has founded or co-founded several biotech companies that are attempting to clinically develop technologies from his lab, including ALXO (SIRP/CD7 antagonist), Synthekine (cytokine engineering), Surrozen (Wnt agonists), 3T (TCR antigen discovery), and Mozart (immune modulation by regulatory T cells)." />
K. Christopher Garcia
Scientific Advisory Board
Kun-Liang Guan
Scientific Advisory Board
Professor Yang-Xin Fu is an endowed Professor at Tsinghua University. He received his Ph.D. in Microbiology and Immunology form University of Miami (1990). He was endowed professor and attending physician in the University of Chicago from 1998 to 2015 and then UT southwestern medical center. 


He has published more than 260 papers with 50,000 citation and H-index of 115 (Clarivate Highly Cited Researchers since 2019).  He made great contribution to the cellular and molecular mechanisms for drug and radiation-induced immunity. His studies have promoted better understanding of traditional therapy and immunotherapy against cancer and infection diseases.  He has been exploring tumor microenvironment and designed next generation of pro-cytokines and pro-antibodies that preferentially activate immune cells inside TME.  His new vaccine platform has been used in patients." />
Yang-Xin Fu
Scientific Advisory Board
Lixin Zhang
Scientific Advisory Board
Alberto Mantovani, MD, is Emeritus Professor of Pathology at the Humanitas University in Milan, Scientific Director of the Istituto Clinico Humanitas and Chair of Inflammation and Therapeutic Innovation, William Harvey Research Institute, Queen Mary University, London, UK.  His attention has been focused on molecular mechanisms of innate immunity and inflammation and on the role in the tumor microenvironment and cancer progression of tumor-associated macrophages (TAM). He has contributed to the advancement of knowledge in the field of Immunology formulating new paradigms and identifying new molecules and functions. 


For his research activity he has received several national and international awards, such as the Triennial OECI Award from the Organization of the European Cancer Institutes, the Robert Koch Award for his contribution to tumor immunology and immunotherapy, the American-Italian Cancer Foundation (AICF) Prize for Excellence in Medicine, the American Association for Cancer Research International Pezcoller Award for Extraordinary Achievement in Cancer Research and, most recently, the CIMT Lifetime Achievement Award. The broad impact of his contributions is testified by citations.  As of June 2023 he has over 161,000 citations and an H-index of 184 (Scopus).


" />
Alberto Mantovani
Scientific Advisory Board
Jun Wang
Scientific Advisory Board
Back
Dr. Jun Zhu
Executive Director

Dr. Jun Zhu, aged 45, has joined the Group since December 2020, and currently serves as the Executive Director and Chief Executive Officer of the Company and holds directorship and other positions in certain subsidiaries of the Company and holds directorship and other positions in certain subsidiaries of the Company.

 

Before joining the Group, Dr. Zhu served as the internal medicine physician in Huashan Hospital affiliated to Fudan University in Shanghai, the project manager and global vice-president of IQVIA Holdings Inc., the general manager in Greater China of Omnicare Clinical Research Inc., the founder and chief executive officer of Shanghai PPC Biopharmaceutical Technology Co., Ltd.*(上海百利佳生醫藥科技有限公司).

 

Dr. Zhu obtained a bachelor’s degree in clinical medicine from Fudan University (復旦大學) in China in July 2001, an EMBA degree from Cheung Kong Graduate School of Business (長江商學院) in China in September 2018 and a doctoral degree in health management from University of Montpellier in June 2024.

  1. Home
  2. About
  3. Dr. Jun Zhu
Back
Privacy Policy
Cookies Policy
Accessibility
Terms of Use
Privacy Policy

Introduction

 

Shanghai Henlius Biotech, Inc., and, where applicable, its affiliates and subsidiaries (collectively, “we” , “us” or “our”) attach great importance to the protection of your privacy and personal information. This Privacy Notice (this “Policy”) is formulated in accordance with applicable PRC laws and regulations governing the protection of personal information in the People’s Republic of China (“PRC”).

 

This Policy applies when: (1) you browse or use our website and other online resources (such as our WeChat official accounts); (2) subscribe to our news or announcements; or (3) contact us through the contact details or other interactive features made available on our website, or otherwise interact with us through our website.. The purpose of this Policy is to explain how and why we process your personal information, the types of personal information involved, applicable retention periods, your rights, and the measures we take to protect personal information. Please read this Policy carefully to ensure that you fully understand its content.

 

In certain business scenarios, we may provide additional explanations regarding the processing of your personal information through separate agreements, privacy statements, or personal information notices. In the event of any inconsistency, such documents shall prevail. For example, where a recruitment function is provided through a third-party platform or service, the relevant third party privacy policy or notice may also apply.

 

For the purposes of this Policy, “personal information” refers to all kinds of information related to identified or identifiable natural persons, excluding anonymized information.

 

We collect, use, store, transfer and otherwise process personal information in strict compliance with applicable PRC laws and regulations of the People’s Republic of China.

 

Our website may contain links to third party websites for your convenience. We do not control, and are not responsible for, the privacy practices of such third parties. We encourage you to review their privacy policies before using those websites.

 

If you have any questions or concerns regarding this Policy or our processing of personal information, please contact us using the details provided below.

 

This Policy will help you understand:

 

I. How we collect your personal information

 

II. How we use your personal information

 

III. How we entrust, share, transfer and publicly disclose your personal information

 

IV. Cross border transfer of personal information

 

V. How we store your personal information

 

VI. Security measures

 

VII. Your rights

 

VIII. Personal information of minors

 

IX. Updates to this Policy

 

X. How to contact us

 

I. How do we collect your personal information?

 

In addition to our employees, we may process personal information of the following persons:

 

• Visitors and users of our website;

 

• Healthcare Professionals;

 

• Investigators of clinical trial institutions and personnel of contract research organizations in clinical trials;

 

• Subjects of clinical trials and their relatives;

 

• Consumers/patients and their relatives using our products or services;

 

• Staff of business partners (including vendors, distributors, partners, etc.); and

 

• Our applicants.

 

We may process personal information of website visitors and individuals who contact or interact with us through our website or other online resources. Depending on the relevant page, function, or interaction, separate privacy notices, consents, platform privacy policies, contracts, or other notices may apply.

 

Based on the context in which you interact with us, we may collect personal information by the following means and on the legal bases permitted by applicable PRC laws and regulations, including your consent, the necessity for entering into or performing a contract, compliance with legal obligations, protection of life, health or property, public health needs, or other circumstances permitted by law:

 

• Your personal information provided to us voluntarily

 

When you subscribe to our news or announcements, contact us through the contact details or other interactive features made available on our website, a third-party platform or service linked or referred to on our website, or otherwise communicate with us in relation to our website, we may collect the personal information that you voluntarily provide, such as your name, contact details, organization, and the content of your inquiry or request, depending on the relevant page or function.

 

• Personal information collected by us independently through our website and other online channels

 

When you visit our website, most of our services do not require any registration, and you can visit our website without telling us who you are. However, some pages or functions may require you to provide certain personal information. If you choose not provide such information as we request, you may not be able to access certain content or functions or we may not be able to respond to your inquiry, request or subscription. Please refer to the relevant page or notice for further details about the categories of personal information collected in a specific scenario.

 

• Personal information we collect from vendors or business partners

 

In the course of our daily business operations, we may collect personal information from our vendors or business partners. We require our vendors and business partners to comply with the requirements of the personal information protection laws and regulations of the PRC and to lawfully provide us with personal information. If you are an employee or representative of one of our vendors or business partners, we may collect personal information such as your name and contact details for the purpose of establishing business contacts and cooperations.

 

• Personal information we collect from publicly available sources

 

We may collect personal information of medical and healthcare professionals from such publicy available sources, such as the official websites of medical institutions and the official websites of competent government departments, and process such information within a reasonable scope and for lawful purposes. For example, for the purpose of lawful academic or professional interaction with healthcare professionals, we may collect the name, gender, employer, position, practitioner registration information, academic title, degree, educational background, specialty expertise, and profile information, where such information has been lawfully made public.

 

Our website may include links, contact details, QR codes, or references to third-party platforms or services. Where you choose to interact with us through such third-party platforms or services, the relevant third party may also process your personal information in accordance with its own privacy policy and applicable law, and we encourage you to review such policy before submitting your information.

 

II. How do we use your personal information?

 

We may use your personal information for the following purposes:

 

• Operating, maintaining and improving our website and other online resource;

 

• Researching, developing, providing and continuously improving our products and services;

 

• Conducting and managing daily business;

 

• Academic interaction with healthcare professionals;

 

• Responding to your inquiries, requests, or communications sent through our website or the contact details made available on our website;

 

• Providing subscription services for our news, announcements, or investor-related updates;

 

• Managing and maintaining our relationship and communications with business contacts who reach us through our website;

 

• Recruiting and human resource management;

 

• Internal compliance management，audit，record-keeping; and

 

• Complying with applicable PRC laws and regulations, for example, monitoring and reporting adverse events for purposes of performing drug quality management responsibilities, providing medical information and dealing with product complaints, etc..

 

We will process personal information only to the extent necessary for the relevant purpose. Where required by applicable law, we will obtain your consent or separate consent before processing your personal information or sensitive personal information. Where a third-party platform or service is used in connection with a particular function, the relevant third party may process your personal information in accordance with its own privacy policy and applicable law.

 

III. How do we entrust, share, transfer and publicly disclose your personal information?

 

1. Entrustment

 

We may entrust our business partners with the processing of your personal information for the purpose(s) described in this Policy. We will enter into appropriate confidentiality, data processing and security agreements with such entrusted parties and require them to process personal information in accordance with our instructions , this Policy and applicable PRC laws and regulations.

 

2. Sharing and public disclosure

 

For the purpose(s) described in this Policy, we will share or publicly disclose your personal information only where permitted by applicable PRC laws and regulations and, where required, after obtaining your consent or separate consent. Such circumstances may include:

 

• Sharing your personal information among our affiliates and subsidiaries where necessary for legitimate business, management, compliance, or operational purposes;

 

• Sharing your personal information with vendors or business partners (such as conference service providers, travel service providers, data service providers, banking or insurance institutions, other professional service organizations, to the extent necessary for the relevant purpose); and

 

• Disclosing your personal information to the extent that it is permitted or required by applicable PRC laws and regulations or for the purpose of assisting with investigations by judicial, regulatory or law enforcement authorities.

 

• other circumstances permitted by applicable PRC laws and regulations.

 

If you submit your information through or in connection with a third-party platform or service referred to on our website, the relevant third party may independently process your personal information in accordance with its own privacy policy and applicable law.

 

3. Transfer

 

We will not transfer your personal information to any other company, entity or individual unless otherwise permitted by applicable law and, where required, after obtaining your consent. Further, in the event of a merger, acquisition, insolvency, reorganization, division, dissolution, bankruptcy, or similar transaction, we will require the new processor of your personal information to continue to be bound by this Policy or we will require the new processor to obtain your consent again.

 

IV.How do we provide your personal information across borders?

 

In principle, personal information that we collect and generate in the course of our operations within the territory of the PRC will be stored within the PRC. In certain circumstances, it may be necessary for us to provide your personal information to recipients outside the PRC in connection with our business operations, website functions, or communications, where permitted by applicable PRC laws and regulations. As required by applicable laws and regulations regarding the protection of personal information, we will provide you with the required notice and obtain your separate consent before providing your personal information across any border, unless otherwise permitted by law. We will use lawful cross-border transfer mechanisms to transfer your personal information oversea and will take necessary measures to ensure that the oversea recipients provide a level of protection required by applicable PRC laws and regulations.

 

You may obtain more information about cross-border transfers of personal information and oversea recipients through the contact methods referred to in this Policy.

 

V. How do we store your personal information?

 

We will retain your personal information for the minimum period necessary to achieve the purposes described in this Policy ,unless a longer retention period is required or permitted by applicable PRC laws and regulations. Upon expiration of the applicable retention period, we will promptly delete or anonymize your personal information in accordance with applicable PRC laws and regulations. Our criteria for determining the period for which personal information shall be retained include:

 

• Applicable laws, regulations and other relevant requirements;

 

• The period of time needed for us to provide services, maintain business relations or interact with you; and

 

• The period of time needed for us to perform relevant agreements or fulfil the purposes described in this Policy.

 

VI. What security measures do we take to protect your personal information?

 

In accordance with applicable PRC laws, regulations, and the requirements of relevant national standards, we take reasonable and appropriate security and precautionary measures to protect the personal information we process against unauthorized access, public disclosure, use, modification, destruction or loss of data. However, you are also responsible for taking appropriate measures to protect the security of the devices, systems, and networks you use when accessing our website or communicating with us.

 

VII. Your rights 

 

In accordance with the requirements of the applicable PRC laws and regulations, you may have the following rights in respect of your personal information:

 

• To know about and make decisions regarding the processing of your personal information;

 

• To access or copy your personal information;

 

• To correct or supplement your personal information;

 

• To delete your personal information;

 

• To request for explanation of rules regarding processing of personal information; and

 

• To change the scope of your consent or revoke your consent , where processing is based on your consent.

 

If you wish to exercise your rights with respect to personal information, you may contact us through the contact information listed in this Policy and we will respond to any request in accordance with applicable relevant laws and regulations. When you exercise the above rights, we may verify your identity to safeguard the security of your personal information. Subject to applicable PRC laws and regulations, there may be circumstances where we are unable to respond to all or part of your request.

 

VIII. How do we process the personal information of minors?

 

For the purposes of this Policy and in accordance with applicable PRC laws and regulations, our products, websites and services are not targeted at minors under the age of 14. Minors under the age of 14 should not provide personal information to us without the consent of a parent or legal guardian.

 

If a minor's personal information is collected with the consent of a parent or legal guardian, we will process the information only when permitted by law, with the express consent of the parent or legal guardian, or necessary for the protection of the minor. If we discover that we have collected personal information without obtaining verifiable prior consent of a parent or legal guardian, we will seek to delete the data as soon as possible.

 

IX. Updates of the Policy

 

We may revise our Privacy Policy from time to time. We will post the updated version on our website and update the “Last Updated” date above or below this Policy.

 

Last updated: March 30, 2026.

 

X. How to contact us?

 

If you have any questions, comments or suggestions concerning this Policy, or any questions or concerns about our processing of your personal information, you may contact us in the following ways:

 

Address: 11/F, B8 Building, No.188 Yizhou Rd, Xuhui District, Shanghai

 

Tel.: 021- 33395800

 

Postal Code: 200233

 

Email: PR@henlius.com

 

Cookies Policy

When you visit our website, we may place small data files known as “cookies” on your device. Cookies enable our website to recognize your browser and help us understand how visitors use the site.

 

Cookies and similar technologies used on this website may collect online identifiers, device information, browser information, IP address, and information about how you interact with the website. In certain circumstances, such information may constitute personal information or may be associated with you under applicable PRC laws and regulations. Information collected through cookies is used for purposes such as ensuring website operation, maintaining security, analyzing traffic and performance, remembering user preferences, and improving website content and user experience.

 

You may choose to accept or decline cookies by adjusting your browser settings or through any cookie banner or preference center made available on our website, if applicable. Please note that disabling cookies may affect the functionality of certain parts of the website.

 

For more information about how we process personal information, please refer to our Privacy Notice.

 

Some cookies may be provided by third parties. Where third-party cookies or similar technologies are used, such third parties may process the relevant information in accordance with their own privacy policies and applicable PRC laws and regulations.

Accessibility

Shanghai Henlius Biotech, Inc. (“Henlius”) is committed to improving the accessibility and user friendliness of its website for all visitors.

 

We strive to ensure that the content on our website can be accessed and used by individuals with diverse needs, including those who rely on assistive technologies. As our website continues to evolve, we recognize that accessibility is an ongoing effort, and we are continuously working to improve usability and accessibility across our digital platforms.

 

If you experience difficulty accessing any part of our website, or have suggestions on how we can enhance accessibility, we welcome your feedback. To help us respond effectively, please include the specific webpage address (URL) and a brief description of the issue encountered.

 

Contact us:

Email: PR@henlius.com

(Please include “Website Accessibility” in the subject line)

Henlius will make reasonable efforts to review accessibility-related feedback and improve the overall online experience for all users. While we strive to improve accessibility, we do not guarantee that every page or feature will be fully accessible to every user in all circumstances.

Terms of Use

This website (http:/) is developed and operated by Shanghai Henlius Biotech, Inc. (“Henlius”). Please read these Terms of Use carefully before accessing or using this website. By accessing, browsing or using this website, you acknowledge that you have read, understood and agreed to be bound by these Terms of Use and applicable PRC laws and regulations.

 

Henlius reserves the right to modify or update these Terms of Use at any time. Any updated version will be posted on this website with a revised “Last Updated” date. Please review them periodically for updates.

 

Prohibited Conduct:

 

You shall not infringe the lawful rights and interests of Henlius or any third party, nor interfere with or attempt to interfere with the normal operation, security, or integrity of this website by any means. Without limitation, you shall not use this website for any unlawful purpose, attempt unauthorized access to any part of the website or related systems, introduce malicious code, scrape or extract website content through automated means, or otherwise interfere with the website’s operation or security features.

 

Copyright

 

All content on this website, including but not limited to text, data, logos, graphics, audio, video and other materials, is owned by Henlius or its respective rights holders, unless otherwise stated. Such content is protected by applicable Chinese and international copyright laws. This website and its content may be accessed and used only for lawful, personal, and non-commercial purposes. Without prior written consent, no entity or individual may copy, reproduce, republish, upload, post, transmit, distribute, modify, create derivative works from, mirror, or otherwise use such content for commercial or public purposes.

 

Disclaimers

 

To the fullest extent permitted by applicable PRC laws and regulations, Henlius makes no warranties or representations, express or implied, regarding the content of this website, including but not limited to accuracy, completeness, timeliness or suitability for any particular purpose. Henlius does not undertake any obligation to update the content of this website , except as otherwise required by applicable PRC laws and regulations.

 

You use this website and any information obtained from it at your own risk. To the fullest extent permitted by applicable PRC laws and regulations, Henlius shall not be liable for any loss or damage arising from the use or inability to use this website, including but not limited to system failures, computer viruses or data loss.

 

Medical Information

 

Nothing on this website constitutes medical advice, diagnosisor treatment recommendations. Medical decisions should always be made in consultation with qualified healthcare professionals. Any product-related or disease-related information provided on this website is provided for general informational purposes only and should not be construed as medical advice, diagnosis, or treatment recommendations; any product information is subject to the approved prescribing information and applicable local laws and regulations.

 

Third Party Websites

 

This website may contain links to third party websites for convenience. Henlius is not responsible for the content, availability, privacy practices, terms or use of such third-party websites. Access to third party websites is at your own risk.

 

Privacy

 

Henlius respects your privacy. Please refer to our Privacy Notice for details.

 

Governing Law

 

These Terms of Use shall be governed by the laws of the People’s Republic of China.

 

Last updated: March 30, 2026

  1. Home